cliexa at Health:Further 2018

On August 27-29, members of the cliexa team, including founder and CEO Mehmet Kazgan, will be attending the Health:Further Conference in Nashville, TN.

The cliexa booth will be in Entrepreneur’s Alley to demo our platforms, and solutions. Angie Buckley, our Director of Business Development, and Ashley Darnell, our Product Manager, are experts at everything cliexa, and will be there everyday. Don’t be shy, come say hello!

This annual healthcare innovation conference is expected to bring in over 2,000 attendees from various healthcare companies, start-ups, and many investors. Health:Further was started in 2015 by Jumpstart Foundry, who selected cliexa as one of their 2018 portfolio companies. cliexa will be accompanied by other avant-garde companies at the conference, such as Vend.RX, Doc&I, LevelTherapy, and more!

If you are attending the conference, we’d love to meet you, and help you learn more about what we do! Find us on the Health:Further mobile app, and reach out to us through direct message. Our team will be available to answer questions. If you cannot find us at the conference, or will not be attending and still want to learn more about what we do, please feel free to contact us! Hope to see you there!

Managing rheumatoid arthritis (RA) can be exhausting in itself. You’re likely juggling medications, doctor appointments, and various lifestyle changes. Since the condition affects people differently and can change from month to month, it’s important to keep track of your symptoms and how you respond to treatments. Having good records can be helpful for your healthcare team.

cliexa-RA has been featured as one of the Best Rheumatoid Arthritis Apps of 2018!

//www.healthline.com/health/best-ra-apps

 

cliexa® partners with the University of Colorado Boulder’s Cognitive and Affective Neuroscience Lab (CANLab) for Multidimensional Pain Tracking and Predictive Analytics Research.
cliexa® Partners with Institute of Cognitive Science at University of Colorado Boulder

Denver, CO, February 28, 2018 — cliexa, Inc., which offers a suite of mobile platforms for chronic disease management, announces its collaboration with CU Boulder’s CANLab and Institute of Cognitive Science (ICS). cliexa will collaborate with CANLab’s team, headed by Tor Wager, a professor of psychology and neuroscience, as they lead in multidimensional pain tracking and predictive analytics research.

CU Boulder jointly filed a provisional patent with cliexa for the multidimensional objective pain concept with CANLab. CANLab focuses on identifying a particular pattern of brain activity, which is diagnostic of physical pain. cliexa-Ease’s mobile platform hosts the research concept and is being used to further develop CANLab’s existing pain studies. cliexa-Ease will deliver an exclusive pain assessment model which, in collaboration with CU Boulder, anticipates commercialization by mid 2018.

Mehmet Kazgan, founder and CEO of cliexa, explains how they are excited about the partnership with Wager’s CANLab because of its “leading research studies for multidimensional pain tracking.” “Working with neuroscientists at CU Boulder is taking the cliexa platform to the next level of objectifying patient outputs with multiple reference points.”

Wager highlights how the collaboration will “expand our ability to understand how emotion affects pain in daily life.” Pavel Goldstein, the scientific lead of the project, adds that the partnership will provide both “an incredible opportunity to establish a platform for researching chronic pain conditions” and “important feedback to pain patients and their clinicians with unique information about patient health.”

About The Cognitive and Affective Neuroscience Lab

Professor Tor Wager leads CANLab, which is housed in CU Boulder’s Institute of Cognitive Science (ICS) and the Psychology and Neuroscience Department. CANLab uses machine-learning to develop fMRI-based biomarkers for clinically relevant outcomes, such as pain. It subsequently tests how psychological factors influence these biomarkers. The lab also engages in collaborative, translational research, which incorporates brain systems-level analyses into the study of clinical disorders, including PTSD, depression, schizophrenia, and chronic pain.

Learn more about CAN Lab at //canlabweb.colorado.edu

About cliexa
The mobile platform technology developed by cliexa enables patients to track their chronic disease activity by quantifying symptoms using scientifically-proven and clinically-validated scoring models. cliexa delivers quantified disease activity and medication adherence through patient reported outcomes through real-time integration to electronic medical records, which streamline processes and increase efficiency in population health management.

Learn more about cliexa at //www.cliexa.com

See the Press release here:

Top 50 Startups to Watch in CO

cliexa is listed as one of the 50 Startups featured in Built in Colorado‘s article:

//www.builtincolorado.com/2018/01/16/50-colorado-tech-startups-watch-2018

Denver, CO, December 19, 2017 — cliexa, Inc., developer of a mobile platform for chronic disease management, announces today a collaboration with Preventative Technology Solutions, Inc., (PTSI), provider of medical assessment applications and mHealth prevention services for adolescents and young adults. cliexa has licensed PTSI assessment technology to launch cliexa-Options, a suite of behavioral health apps for primary care and family medicine physicians which will help determine risk level for sexual activity, substance use and other issues. UC Health Longmont is piloting the sexual risk assessment app in its clinic and the service is reimbursable by major insurance providers.

Half of the nearly 20 million new sexually transmitted diseases (STDs) reported each year were among young people between the ages of 15 to 24 and nearly 230,000 babies were born to teen girls aged 15–19 years in 2015, according to the CDC. Undiagnosed STDs cause infertility in 20,000 women annually. Facilitating conversations between patients and their physicians is a significant step necessary to reduce costs and chronic conditions often associated with adolescent behavioral health.

cliexa-Options delivers precise, evidence-based assessments that patients complete on a tablet in the physician’s office before their appointment, creating a structured report using proprietary algorithms for each risk area. The reproductive health app supports early identification of patients at highest risk of acquiring an STD or experiencing an unplanned pregnancy. The mental health and substance use apps identify mental health screening, substance use and resiliency in patients.

cliexa is adding cliexa-Options to its award-winning, digital health platform specializing in patient-reported outcomes and value-based care. The company has partnered with Kaiser Permanente Colorado Rheumatology Clinic at Rock Creek and Colorado Permanente Medical Group since 2016, piloting cliexa-RA for rheumatoid arthritis disease management.

“We are excited to partner with PTSI in providing solutions for adolescent behavioral health,” said Mehmet Kazgan, founder and CEO of cliexa. “Our vision is to build an ecosystem for patients and care teams using the most effective and clinically-validated assessment models and patient-reported outcomes. Combining PTSI’s expertise with cliexa’s digital platform creates state-of-the art products in this space.”

“This is an exciting collaboration, and we anticipate being able to serve our medical providers with better digital health technology services in underutilized areas of primary care,” said Scott Fowle, CEO of Preventative Technology Solutions.

About PTSI
Founded in 2015, PTSI provides health promotion software on a service basis for providers who work with adolescents and emerging adults. The apps improve assessment and treatment outcomes for sexual heath, mental health and substance abuse risks, allowing patients to collaborate with providers to establish healthy behaviors. PTSI technology supports access to population data to analyze, and further understand and improve treatment outcomes. Learn more about PTSI at //www.mypreventtech.com.

About cliexa
The mobile platform technology developed by cliexa enable patients to track their chronic disease activity by quantifying symptoms using scientifically-proven and clinically-validated scoring models. cliexa delivers quantified disease activity and medication adherence through patient reported outcomes by real-time integration to electronic medical records which streamlines processes and increases efficiency in population health management.

Learn more about cliexa at //www.cliexa.com

Press Release:

//www.pr.com/press-release/739441